Ypke van Oosterhout, Ph.D. | Executive Director
Ypke van Oosterhout is the founder and CEO of Xenikos B.V. and the pioneering scientist behind T-Guard’s development. Ypke discovered T-Guard while working in the Hematology Department of Radboud University Nijmegen Medical Center (the Netherlands) after earning his Masters Degree in biology from the University of Nijmegen. Recognizing T-Guard’s clinical potential, Ypke focused his Ph.D. on its mode of action, safety and efficacy.
Following early positive clinical results, Ypke was awarded a STIGON Grant from the Dutch government initiative
Following further development of T-Guard within Immunotoko B.V., a company founded by the Radboudumc and Ypke, and Henogen (now Novasep Belgium), he founded Xenikos B.V. in 2009 with the aim of completing the development of T-Guard to registration as an orphan drug for the treatment acute GVHD and other indications.